{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:27:08Z","timestamp":1790116028763,"version":"4.0.1"},"reference-count":58,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11\/01132"],"award-info":[{"award-number":["PI11\/01132"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/01195"],"award-info":[{"award-number":["PI14\/01195"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00276 cofinanced by FEDER Funds from the European Comission \"A way of making Europe\""],"award-info":[{"award-number":["PI17\/00276 cofinanced by FEDER Funds from the European Comission \"A way of making Europe\""]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["REDinREN\/RD16\/0009\/0026"],"award-info":[{"award-number":["REDinREN\/RD16\/0009\/0026"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["S2017-BMD-3686 (CIFRA2-CM)"],"award-info":[{"award-number":["S2017-BMD-3686 (CIFRA2-CM)"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Senefro","award":["Nephrology research grant SENEFRO 18\/01"],"award-info":[{"award-number":["Nephrology research grant SENEFRO 18\/01"]}]},{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["Research grant 2020"],"award-info":[{"award-number":["Research grant 2020"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin). Prophylaxis was with imipenem\/cilastatin. Cilastatin is a selective inhibitor of renal dehydropeptidase I in the proximal renal tubule cells that can reduce the nephrotoxicity of cisplatin. Unfortunately, cilastatin is not currently marketed alone, and can only be administered in combination with imipenem. The study has a retrospective part that serves as a control (n = 99 patients receiving standard surgical prophylaxis) and a prospective part with imipenem\/cilastatin prophylaxis corresponding to the study group (n = 85 patients). In both groups, we collected specific data on preoperative risk factors of renal damage, fluid management, hemodynamic control, and urine volume during surgery (including the hyperthermic chemotherapy perfusion), as well as data on hemodynamic and renal function during the first seven days after surgery. The main finding of the study is that cilastatin may exert a nephroprotective effect in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal cisplatin perfusion. Creatinine values remained lower than in the control group (ANOVA test, p = 0.037). This translates into easier management of these patients in the postoperative period, with significantly shorter intensive care unit (ICU) and hospital stay.<\/jats:p>","DOI":"10.3390\/ijms22031239","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T06:10:54Z","timestamp":1611727854000},"page":"1239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.3390","volume":"22","author":[{"given":"Matilde","family":"Zaballos","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"},{"name":"Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-3135","authenticated-orcid":false,"given":"Mercedes","family":"Power","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0416-4817","authenticated-orcid":false,"given":"Mar\u00eda Iluminada","family":"Canal-Alonso","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"},{"name":"Department of Legal Medicine, Psychiatry and Pathology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gonz\u00e1lez-Nicol\u00e1s","sequence":"additional","affiliation":[{"name":"Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"},{"name":"Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenceslao","family":"Vasquez-Jimenez","sequence":"additional","affiliation":[{"name":"Peritoneal and Retroperitoneal Unit, Department of Surgery, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-8449","authenticated-orcid":false,"given":"Pablo","family":"Lozano-Lominchar","sequence":"additional","affiliation":[{"name":"Peritoneal and Retroperitoneal Unit, Department of Surgery, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Cabrerizo-Torrente","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Palencia-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Peritoneal and Retroperitoneal Unit, Department of Surgery, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Gago-Quiroga","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Ginel-Feito","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-679X","authenticated-orcid":false,"given":"Alberto","family":"L\u00e1zaro","sequence":"additional","affiliation":[{"name":"Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"},{"name":"Department of Physiology, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Gonz\u00e1lez-Bay\u00f3n","sequence":"additional","affiliation":[{"name":"Peritoneal and Retroperitoneal Unit, Department of Surgery, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28040 Madrid, Spain"},{"name":"Department of Surgery School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"ref_2","first-page":"83","article-title":"Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer","volume":"16","author":"Sugarbaker","year":"1989","journal-title":"Semin. Oncol."},{"key":"ref_3","unstructured":"Sugarbaker, P.H. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal Carcinomatosis: Principles of Management, Kluwer Academic Publishers."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: Rationale and technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1245\/s10434-007-9462-0","article-title":"Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms","volume":"14","author":"Yan","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0035-1564431","article-title":"Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy","volume":"28","author":"Nadler","year":"2015","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/0265673021000035235","article-title":"The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours","volume":"19","author":"Takemoto","year":"2003","journal-title":"Int. J. Hyperth."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","article-title":"Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies","volume":"12","author":"Oh","year":"2014","journal-title":"Electrolyte Blood Press."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1245\/s10434-012-2853-x","article-title":"Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Canda","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ejso.2015.12.016","article-title":"Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances","volume":"42","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.110.165779","article-title":"Cilastatin attenuates cisplatin-induced proximal tubular cell damage","volume":"334","author":"Lazaro","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/ndt\/gfx005","article-title":"Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection","volume":"32","author":"Humanes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1194\/jlr.M080465","article-title":"Lipid imaging for visualizating cilastatin amelioration of cisplatin-induced nephrotoxicity","volume":"59","author":"Aboulmagd","year":"2018","journal-title":"Lipid Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/ac201933x","article-title":"Elemental bioimaging in kidney by LA-ICP-MS as a tool to study nephrotoxicity and renal protective strategies in cisplatin therapies","volume":"83","author":"Giesen","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2012.199","article-title":"Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats","volume":"82","author":"Humanes","year":"2012","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/ckj\/sfaa193","article-title":"Cilastatin: A potential treatment strategy against COVI-19 that may decrease viral replication and protect from the cytokine storm","volume":"13","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1185\/030079906X167633","article-title":"Cilastatin protection against cyclosporin A-induced nephrotoxicity: Clinical evidence","volume":"23","author":"Tejedor","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0041-1345(98)00523-5","article-title":"Imipenem\/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients","volume":"30","author":"Carmellini","year":"1998","journal-title":"Transplant. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00007890-199403270-00017","article-title":"Reduction of cyclosporine induced nephrotoxicity by cilastatin following clinical heart transplantation","volume":"57","author":"Markewitz","year":"1994","journal-title":"Transplantation"},{"key":"ref_24","first-page":"CD003590","article-title":"Interventions for protecting renal function in the perioperative period","volume":"9","author":"Zacharias","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","first-page":"1528","article-title":"Hyperthermic intraperitoneal chemotherapy is an independent risk factor for development of acute kidney injury","volume":"23","author":"Dagel","year":"2018","journal-title":"J BUON"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3109\/0886022X.2014.949758","article-title":"The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery","volume":"36","author":"Hakeam","year":"2014","journal-title":"Renal Fail"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00467-017-3765-6","article-title":"Identifying cisplatin-induced kidney damage in paediatric oncology patients","volume":"33","author":"Barton","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s11605-015-2743-1","article-title":"A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"19","author":"Colantonio","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1124\/jpet.105.087601","article-title":"Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels","volume":"314","author":"Dickey","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejso.2015.07.016","article-title":"Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment","volume":"42","author":"Bouhadjari","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_32","first-page":"207","article-title":"Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study","volume":"92","author":"Vaira","year":"2001","journal-title":"Minerva Med."},{"key":"ref_33","first-page":"761","article-title":"Nephroprotective effect of cilastatin in allogeneic bone marrow transplantation. Results from a retrospective analysis","volume":"18","author":"Gruss","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/02656736.2017.1368096","article-title":"Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective study","volume":"34","author":"Cata","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/02656736.2017.1293304","article-title":"Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy","volume":"33","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Galfetti, E., Cerutti, A., Ghielmini, M., Zucca, E., and Wannesson, L. (2020). Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-0398-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.suronc.2016.03.007","article-title":"Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study","volume":"25","author":"Feliciangeli","year":"2016","journal-title":"Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamasurg.2017.2865","article-title":"Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"152","author":"Eng","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13054-019-2516-4","article-title":"Hemodynamic goal-directed therapy and postoperative kidney injury: An updated meta-analysis with trial sequential analysis","volume":"23","author":"Giglio","year":"2019","journal-title":"Crit. Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-micro-090110-102911","article-title":"Epidemiological expansion, structural studies, and clinical challenges of new \u03b2-lactamases from gram-negative bacteria","volume":"65","author":"Bush","year":"2011","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/cc4915","article-title":"RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis","volume":"10","author":"Hoste","year":"2006","journal-title":"Crit. Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-6143.2006.01602.x","article-title":"Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation","volume":"7","author":"Wong","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.2017080882","article-title":"Causes of Death after a Hospitalization with AKI","volume":"29","author":"Silver","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2011.405","article-title":"Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury","volume":"81","author":"Bucaloiu","year":"2012","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"704382","DOI":"10.1155\/2015\/704382","article-title":"Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity","volume":"2015","author":"Humanes","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jado, J.C., Humanes, B., Gonz\u00e1lez-Nicol\u00e1s, M.A., Cama\u00f1o, S., Lara, J.M., L\u00f3pez, B., Cercenado, E., Garc\u00eda-Bordas, J., Tejedor, A., and L\u00e1zaro, A. (2020). Nephroprotective Effect of Cilastatin against Gentamicin-Induced Renal Injury In Vitro and In Vivo without Altering Its Bactericidal Efficiency. Antioxidants, 9.","DOI":"10.3390\/antiox9090821"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfh397","article-title":"Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells","volume":"19","author":"Castilla","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_50","unstructured":"Gallelli, L. (2012). Novel strategies in drug-induced acute kidney injury. Pharmacology, Intech."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drup.2005.02.003","article-title":"Role of early plasma membrane events in chemotherapy-induced cell death","volume":"8","author":"Meurette","year":"2005","journal-title":"Drug Resist. Update"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Holditch, S.J., Brown, C.N., Lombardi, A.M., Nguyen, K.N., and Edelstein, C.L. (2019). Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123011"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2016060606","article-title":"Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity","volume":"28","author":"Hori","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ckj\/sfs160","article-title":"The RIFLE and AKIN classifications for acute kidney injury: A critical and comprehensive review","volume":"6","author":"Lopes","year":"2013","journal-title":"Clin. Kidney J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jso.21068","article-title":"The intraoperative staging systems in the management of peritoneal surface malignancy","volume":"98","author":"Portilla","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jso.21072","article-title":"Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy","volume":"98","author":"Kusamura","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_57","unstructured":"Sugarbaker, P.H. (2005). Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancy, The Ludann Company. [4th ed.]."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00228-012-1405-4","article-title":"Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis","volume":"69","author":"Cashin","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:16:00Z","timestamp":1760159760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22031239"],"URL":"https:\/\/doi.org\/10.3390\/ijms22031239","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]}}}